LOXO ONCOLOGY,INC. (NASDAQ:LOXO) Files An 8-K Regulation FD Disclosure

ME Staff 8-k
-
0

LOXO ONCOLOGY,INC. (NASDAQ:LOXO) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD.

On February21, 2018, Loxo Oncology,Inc. (“Loxo Oncology”) issued a press release announcing the publication of larotrectinib clinical data in the New England Journal of Medicine. A copy of the press release is furnished as Exhibit99.1 to this report and incorporated herein by reference. Loxo Oncology undertakes no obligation to update, supplement or amend the materials attached hereto as Exhibit99.1.

The information furnished with this report, including Exhibit99.1, shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits

(d)Exhibits.


Loxo Oncology, Inc. Exhibit
EX-99.1 2 a18-6502_1ex99d1.htm EX-99.1 Exhibit 99.1     Loxo Oncology Announces Publication of Larotrectinib Clinical Data in The New England Journal of Medicine   — Marked and Durable Responses Across TRK Fusion Cancers —   — 75 Percent Overall Response Rate by Central Assessment; 80 Percent Overall Response Rate by Investigator Assessment —   — 86 Percent of Responding Patients Remain on Larotrectinib or Underwent Surgery with Curative Intent —   — Median Duration of Response and Progression-Free Survival Not Reached —   STAMFORD,…
To view the full exhibit click here

About LOXO ONCOLOGY,INC. (NASDAQ:LOXO)

Loxo Oncology, Inc. is a United States-based biopharmaceutical company. The Company is engaged in developing selective medicines for patients with genetically defined cancers. Its pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer. Its pipeline includes LOXO-101, LOXO-195, Rearranged During Transfection (RET) Program and Fibroblast Growth Factor Receptor (FGFR) program. LOXO-101 is a selective inhibitor of tropomyosin receptor kinases (TRK) for the treatment of patients with soft tissue sarcoma. LOXO-195 is a selective TRK inhibitor capable of addressing potential mechanisms of acquired resistance that may emerge in patients receiving LOXO-101 or multikinase inhibitors with anti-TRK activity. It has designed a series of RET inhibitors that optimize on-target potency for RET gene fusions, mutations and clinically-identified resistance mutations. It is designing FGFR1-sparing FGFR inhibitor.